Company intelligence / Profile preview
Lobsor Pharmaceuticals
- Ownership
- Private
- Development stage
- Other
Overview
Lobsor Pharmaceuticals has developed Lecigon, a proprietary gel formulation combining levodopa, carbidopa, and entacapone for continuous intestinal infusion in advanced Parkinson’s disease. Lecigon is approved in Sweden and some European markets. The therapy aims to improve motor fluctuations and reduce side effects associated with high-dose levodopa by enabling lower dosing through the addition of entacapone. Clinical results indicate improved convenience, reduced 3‑OMD metabolite levels, and better quality of life for patients[1][7][10].
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeGel formulation
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Lobsor Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lobsor Pharmaceuticals.